CVD disproportionately affects Māori and Pacific peoples: 2.6–2.8 times more years are lost to cardiovascular events relative to non-Māori/non-Pacific peoples.2 This is despite the availability in New Zealand of highly cost-effective medicines for CVD prevention.
New Zealanders of European ethnicity with CVD (as identified by hospital discharge codes) are more likely to be taking CVD medicines compared with other ethnic groups. After adjustment for comorbidities that may limit aggressive secondary CVD prevention, in 2019 more people of European/Other ethnicity were on at least one of the three groups of CVD medicines (91 per cent) compared with Māori (83 per cent) or Pacific peoples (84 per cent).3
Significant opportunities in improving CVD medicines use remain. People with CVD have very high contact rates with primary healthcare and PHO enrolment rates. The high proportions of CVD patients who had at least one primary healthcare consult (96.9 per cent) in 2019 or were currently enrolled in a PHO in 2020 (99.2 per cent) provide a valuable opportunity for proactive care, eg, system alert set-ups, for the management of secondary prevention in people with CVD.3